Hepatocellular Cancer

P=N/A, N=4, Terminated, Assistance Publique - Hôpitaux de Paris | N=120 --> 4 | Trial completion date: Sep 2027 --> Sep 2025 | Recruiting --> Terminated; Abandon of study

P=N/A, N=100, Not yet recruiting, Assiut University

Furthermore, the OST inhibitor NGI-1 and NGI-1-loaded nanoparticles exerted potent antitumor effects and further augmented the efficacy of lenvatinib and immunotherapy. These findings highlight DDOST as a promising therapeutic target to improve treatment outcomes in HCC.

Notably, NPM1 expression correlates with elevated WNT signaling and proliferation in human colorectal cancer (CRC), while CRCs harboring NPM1 deletions exhibit preferential TP53 inactivation, underscoring the clinical relevance of our findings. Being dispensable for adult epithelial homeostasis, NPM1 represents a promising therapeutic target in p53-proficient WNT-driven tumors, including treatment-refractory KRAS-mutant CRC, and hepatic cancers.

Overexpression of Alkbh5 increased Hspb1 expression and inhibited ferroptosis, indicating that Alkbh5 regulates ferroptosis through targeting Hspb1. Targeting Alkbh5/Hspb1/ferroptosis axis may enhance anti-tumor effects in combination therapy, highlighting a potential therapeutic approach for HCC.

Proteomic profiling reveals that responders exhibit lower baseline IFN-γ and elevated IL-6, while post-SBRT increases in IFN-γ, IL-2, and IL-6 correlate with improved outcomes. These results indicate that combination of SBRT in ICI-refractory HCC is effective, well-tolerated, and may be guided by cytokine assessment.

This study, integrating computational analysis, including network target and bioinformatics, with cellular experimental validation, reveals the inhibitory potential of PZH on hepatocellular carcinoma progression through the regulation of cell cycle-related pathways and biological processes. Notably, this study provides the first mechanistic insight into how PZH intervenes in the multi-step hepatocarcinogenesis, highlighting its potential role in preventing liver cancer development.

P1, N=70, Recruiting, Myeloid Therapeutics | N=48 --> 70 | Trial completion date: May 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> Dec 2027

P3, N=300, Recruiting, Polaris Group | Trial completion date: Oct 2025 --> Dec 2028 | Trial primary completion date: Sep 2025 --> Sep 2028

Herein, we describe the evaluation of the anti-fibrotic effects of novel colchicine derivatives, namely, a water-soluble colchicinoid (4) and a retinoid acid-colchicine conjugate (5) in its liposomal formulation (L2) to target hepatic stellate cells (HSC)...Both 4 and L2 are suitable for practical treatment of LF with appropriate doses. The liposomal formulation L2 demonstrated an improved safety profile.

In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.

Baseline EMT/adhesion signatures and stress-response pathways nominate CD44 and ITGA3/α3β1 as candidate biomarkers of resistance. These findings delineate molecular programs of β-emitter radioresistance and identify candidate pathways for future targeting.